Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease ... Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). 詳細を表示
CAHmelia-204 Study of 200mg Once-Daily (QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction Dose-Ranging Data from...
Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0579 | 15.1531012824 | 0.3821 | 0.445 | 0.365 | 546494 | 0.40171406 | CS |
4 | -0.1026 | -18.9089568743 | 0.5426 | 0.574 | 0.365 | 929492 | 0.45599028 | CS |
12 | 0 | 0 | 0.44 | 0.608 | 0.365 | 559066 | 0.48652122 | CS |
26 | -0.105 | -19.2660550459 | 0.545 | 0.608 | 0.365 | 483139 | 0.48594225 | CS |
52 | -2.14 | -82.9457364341 | 2.58 | 5.95 | 0.365 | 683158 | 1.1177144 | CS |
156 | -3.21 | -87.9452054795 | 3.65 | 5.95 | 0.365 | 523619 | 2.14037885 | CS |
260 | -16.56 | -97.4117647059 | 17 | 35.6 | 0.365 | 548910 | 3.28795644 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約